Adipex diet pill works by affecting parts of the central nervous system, which effectively suppress hunger, and therefore, cravings. The Adipex diet pill is known to increase levels of energy within patients, which is ideally expended through exercise and being generally active.
Since the Adipex diet pill affects (and controls) the amount of signalling to the part of your brain that manages appetite, it is very effective in helping you manage how much you actually eat. The result of this effect, is that you will be more satisfied with less food when taking Adipex, more so than when you are not taking the diet pill. The other effect of Adipex, is that it increases your energy, so you can easily burn off the calories more easily.
CONTRAVE® is a prescription-only, FDA-approved weight-loss pill believed to work on two areas of your brain—the hunger center and the reward system—to reduce hunger and help control cravings. CONTRAVE contains two medicines, bupropion and naltrexone. CONTRAVE has a well-studied safety and tolerability profile. Three long-term (56 weeks) studies have shown that patients who add CONTRAVE lose approximately 2 to 4 times more weight than with diet and exercise alone. 3 In one study, patients who also participated in an intensive diet and exercise program and remained on CONTRAVE for a full year, lost 25 pounds on average.
Saxenda® (liraglutide) injection 3 mg is an injectable prescription medicine that may help some adults with excess weight (BMI ≥27) who also have weight-related medical problems or obesity (BMI ≥30) lose weight and keep the weight off. Saxenda® should be used with a reduced-calorie meal plan and increased physical activity. These results were from a 56-week trial of adults with excess weight (BMI ≥27) with at least 1 weight-related condition, or obesity (BMI ≥30), not including patients with type 2 diabetes. On average, 27% of people on Saxenda® and 34% on placebo did not complete the study. In the study, 62% of patients on Saxenda® lost ≥5% of their body weight (vs 34% placebo) and 34% lost ≥10% body weight (vs 15% placebo). Significant weight loss was only evaluated at 56 weeks, as per study design.
Qsymia is a combination of phentermine, a sympathomimetic amine anorectic, and topiramate extended-release, an antiepileptic drug, indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of: • 30 kg/m2 or greater (obese) (1) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes mellitus, or dyslipidemia (1)